News

Back

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europ

November 10th 2022

BSCB Dev

 Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders and the Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company focused on CNS therapies, today announce the completion of a strategic license agreement

Read Pdf